Sarmen Sarkissian, MD ATR depletion has been implicated as a tumor targeting strategy in prior reports. In this study published by Thomas et al, the addition of a M6620 has shown an improvement in responsiveness to topotecan in a small phase I clinical trial. 21 patients with various different solid malignancies were enrolled in this study. The ATR-CHK2 pathway has been well implicated in promoting cancer cell survival. This is the first report of the combination of an ATR inhibitor in combinati [...]
